
    
      A multicenter, randomized, double-blind, placebo-controlled clinical trials will be conducted
      to determine whether the NBZP could make an effect of pain relief and joints protection. 120
      patients suffering from active RA will be enrolled and treated with NBZP or placebo for 3
      months. The primary outcome measures are the rate of American College of Rheumatology (ACR)
      50, changes of the Disease Activity Score (DAS) 28 from the baseline to 3 months and the van
      der Heijde modified Sharp score would be measured from the baseline to 12 months. The second
      outcome measures are the change rate of ACR20, ACR70, Health Assessment Questionnaire -
      Disability Index, change score of Patient Assessment of Arthritis Pain, Patient Global
      Assessment of Arthritis, Patient Global Assessment of Arthritis and the Athens Insomnia Scale
      (AIS) from the baseline to 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months'
      follow-up.
    
  